Angioedema Market to Reach USD 7.9 Billion by 2034

Angioedema is a condition characterized by sudden swelling in the deeper layers of the skin, often affecting the face, lips, tongue, throat, and extremities. It can be hereditary, acquired, drug-induced (commonly linked to ACE inhibitors), or idiopathic. Severe cases, particularly involving the airway, can be life-threatening.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71681

While antihistamines, corticosteroids, and epinephrine are often used in acute allergic angioedema, hereditary angioedema (HAE) has unique treatment pathways involving C1 esterase inhibitors, bradykinin B2 receptor antagonists, and kallikrein inhibitors. Growing awareness, improved diagnostic tools, and the approval of novel therapies are significantly transforming the market outlook. Between 2024 and 2034, the global angioedema market is expected to expand steadily, driven by innovation and patient advocacy.

Market Overview
The global Angioedema market size in 2024 is estimated at USD 4.2 billion and is projected to reach USD 7.9 billion by 2034, growing at a CAGR of 6.8% (2024-2034).

Key highlights:
• Rising prevalence of drug-induced and idiopathic angioedema worldwide.
• Expanding therapeutic pipeline for hereditary angioedema (HAE) patients.
• Growing use of self-administered and prophylactic therapies.
• Increasing rare disease awareness programs and advocacy networks.
• Challenges include high costs of biologics, limited awareness in developing regions, and diagnosis delays.

Leading companies such as Takeda, CSL Behring, BioCryst Pharmaceuticals, and Pharming Group are actively driving innovation in the angioedema treatment space.

Segmentation Analysis
The angioedema market can be segmented as follows:

• By Product
o Antihistamines
o Corticosteroids
o Epinephrine
o C1 esterase inhibitors
o Kallikrein inhibitors
o Bradykinin B2 receptor antagonists
o Monoclonal antibodies

• By Platform
o Small molecules
o Biologics
o RNA-based drugs
o Gene therapies

• By Technology
o Protein replacement therapy
o Antibody engineering
o RNA interference (RNAi)
o Gene-editing technologies

• By End Use
o Hospitals
o Specialty clinics
o Homecare settings

• By Application
o On-demand treatment
o Prophylactic treatment
o Research applications

Segmentation Summary:
For acute allergic angioedema, antihistamines, corticosteroids, and epinephrine dominate. However, in hereditary angioedema, the focus is shifting toward long-term prophylactic treatments, particularly subcutaneous therapies and monoclonal antibodies. Homecare settings are gaining popularity due to the growing availability of self-injectable drugs.

Explore Full Report here: https://exactitudeconsultancy.com/reports/71681/angioedema-market

Regional Analysis
• North America
Largest market in 2024, owing to advanced healthcare infrastructure, strong patient advocacy groups, and widespread adoption of novel biologics.
• Europe
Second-largest market, supported by orphan drug designations, growing genetic testing adoption, and major pharma presence in Germany, France, and the UK.
• Asia-Pacific
Fastest-growing region, with increasing prevalence of ACE inhibitor-induced angioedema, rising rare disease awareness, and expanding pharma investments in Japan, China, and India.
• Middle East & Africa
Growth remains limited due to diagnostic challenges and affordability barriers, though partnerships with international players are improving patient access.
• Latin America
Brazil and Mexico lead growth, supported by emerging healthcare programs, though reimbursement challenges persist.
Regional Summary:
North America and Europe dominate revenues, but Asia-Pacific is expected to post the highest CAGR through 2034, making it a key strategic focus for global biopharma companies.

Market Dynamics
Key Growth Drivers
• Increasing Prevalence: Rising cases of drug-induced and hereditary angioedema.
• Pipeline Expansion: Next-generation kallikrein inhibitors and monoclonal antibodies under development.
• Supportive Regulatory Pathways: Orphan drug designations and fast-track approvals.
• Improved Awareness: Advocacy programs driving early diagnosis and patient education.

Key Challenges
• High Cost of Therapies: Biologics and orphan drugs remain expensive.
• Regional Disparities: Limited infrastructure in low-income economies.
• Treatment Adherence: Chronic management requires continuous therapy, impacting compliance.
• Safety Concerns: Long-term effects of novel therapies still under investigation.

Latest Trends
• Shift toward self-administered subcutaneous therapies.
• Growing focus on prophylactic treatments for HAE patients.
• Research into RNA-based and gene-editing therapies for long-term solutions.
• AI-driven patient monitoring tools for better disease management.
• Strategic collaborations between biotech and pharma to accelerate commercialization.

Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71681

Competitor Analysis
Major players in the angioedema market include:
• Takeda Pharmaceutical Company Limited
• CSL Behring
• BioCryst Pharmaceuticals
• Pharming Group N.V.
• Ionis Pharmaceuticals
• KalVista Pharmaceuticals
• Adverum Biotechnologies
• Intellia Therapeutics
• Pharvaris
• Sanofi

Competitive Summary:
Takeda leads with its robust HAE portfolio, while CSL Behring and Pharming continue to dominate with C1 esterase inhibitors and recombinant therapies. BioCryst has made notable advances in oral prophylactic kallikrein inhibitors, and Ionis is driving RNA-based innovation. Emerging players like Pharvaris and Intellia are exploring gene-editing and next-generation biologics, intensifying competition.

Conclusion
The global angioedema market is projected to grow from USD 4.2 billion in 2024 to USD 7.9 billion by 2034, at a CAGR of 6.8%.

Future growth will be driven by next-generation prophylactic therapies, patient-friendly formulations, and genetic innovation. While high costs and limited awareness pose challenges, the expanding therapeutic pipeline and rising prevalence will ensure continued momentum.

Key Takeaway: The angioedema market is evolving rapidly, with a shift from acute management to long-term preventive care. Companies investing in affordability, accessibility, and innovative biologics will be well-positioned to lead through 2034.

This report is also available in the following languages : Japanese (血管性浮腫市場), Korean (혈관부종 시장), Chinese (血管性水肿市场), French (Marché de l'angio-œdème), German (Angioödem-Markt), and Italian (Mercato dell'angioedema), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71681/angioedema-market#request-a-sample

Our More Reports:

Cataract Surgery Complications Market
https://exactitudeconsultancy.com/reports/72247/cataract-surgery-complications-market

Central Serous Chorioretinopathy Market
https://exactitudeconsultancy.com/reports/72248/central-serous-chorioretinopathy-market

Centronuclear Myopathy Market
https://exactitudeconsultancy.com/reports/72249/centronuclear-myopathy-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.